Carisma Therapeutics Inc. (CARM)

3.09 ↑0.06 (1.98%)

As of March 30, 2023, 3:59pm EST.

Summary
Stock Details

CARM Chart

52-Week Range: $2.88 - $15.87
Market Capitalization: $0
Short Percentage: 0%

Target Price: $0.00
Shares Outstanding: 201M
Next Earnings: N/A

View More Stats

Catalysts

DateCategoryCatalyst

No upcoming catalysts found

Help your fellow traders

News and Press Releases

We searched over 50 sources and couldn't find any news or press releases related to Carisma Therapeutics.

Here are some articles we think you might like.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Inspirato Incorporated and Encourages Investors with Losses to Contact the Firm
Accesswire | March 30th
ISPO
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the Firm
Accesswire | March 30th
IVVD
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
GlobeNewsWire | March 30th
GPCR
XWELL Announces Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K And Provides Preliminary FY2022 Operating Update
GlobeNewsWire | March 30th
XWEL
Molekule Reports Fourth Quarter and Full Year 2022 Financial Results
GlobeNewsWire | March 30th
MKUL
Pineapple Energy Reports Fourth Quarter 2022 Financial Results
GlobeNewsWire | March 30th
PEGY
Silver Spike Investment Corp. Reports Fiscal Year End 2022 Financial Results
GlobeNewsWire | March 30th
SSIC
TeraWulf Reports Fourth Quarter and Full Year 2022 Results and Provides Operational Update
Business Wire | March 30th
WULF
Rumble Reports Record Fourth Quarter and Full Year 2022 Results
GlobeNewsWire | March 30th
RUM
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
GlobeNewsWire | March 30th
LSTA
Expion360 Reports 2022 Revenue up 59% to Record $7.2 Million
Accesswire | March 30th
XPON
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
GlobeNewsWire | March 30th
GRNA
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
GlobeNewsWire | March 30th
ICVX
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
GlobeNewsWire | March 30th
ABSI
ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
GlobeNewsWire | March 30th
OSA

Company Info

Website: N/A
Address: N/A
Sector: N/A
Industry: N/A
Full time employees: 92

Stock Details

Current Price: $3.09
52-Week Low: $2.88
52-Week High: $15.87
Most Recent Quarter: 0000-00-00

Shares Float: 0
Shares Outstanding: 201M
Market Capitalization: $0
Next Earnings Date: N/A

Short Interest

Shares Short
(Today): 0
Short Ratio: 0.00

Shares Short
(Last Month): 0
Short Interest: 0.00%

The short interest for Carisma Therapeutics Inc. is at 0.00%, which is low amongst its peers.

Stock Ownership

Retail: 100.00%

Insiders: 0.00%

Instutitions: 0.00%

Analyst Target Price

0.00

Carisma Therapeutics Inc. is currently $3.03 above Wallstreet Analysts' price target.

Yesterday's Volume

46,746

Interest in Carisma Therapeutics Inc. has been trending down. The average daily volume in the past 14 days is 153,967.

Discussions

Please log in or register to share your thoughts.

No comments yet. Be the first.